Investors News Releases Sign up for email alerts to receive company and investor updates News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Annual Reports News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Dec 15 2009 Cyclacel receives NASDAQ notice of non-compliance Dec 15 2009 Cyclacel provides update on meeting with FDA to discuss pivotal study design for sapacitabine Dec 05 2009 Cyclacel reports Phase 2 sapacitabine data in acute myeloid leukemia and myelodysplastic syndromes at 2009 ASH annual meeting Dec 01 2009 Cyclacel to host conference call on Monday, December 7 to discuss new Phase 2 sapacitabine data to be presented at ASH Nov 30 2009 Sapacitabine phase 1 data published in acute leukemia and myelodysplastic syndromes Nov 17 2009 Cyclacel Pharmaceuticals to present Sapacitabine Phase 2 AML & MDS data at the upcoming American Society of Hematology meeting Nov 03 2009 Cyclacel Announces Third Quarter 2009 Financial Results Oct 30 2009 Cyclacel Receives Deficiency Notice From Nasdaq Global Select Market Oct 28 2009 Cyclacel reports survival data from phase 2 sapacitabine study in elderly patients with acute myeloid leukemia Oct 28 2009 Cyclacel Pharmaceuticals third quarter 2009 financial results conference call on Tuesday November 3 & upcoming conference presentations Oct 21 2009 Cyclacel Pharmaceuticals to present at BIO Investor Forum Sep 03 2009 Cyclacel to present at Annual Rodman & Renshaw Healthcare Conference Aug 28 2009 Cyclacel Pharmaceuticals announces receipt of NASDAQ notice Aug 06 2009 Cyclacel Pharmaceuticals announces second quarter 2009 financial results Jul 31 2009 Cyclacel Pharmaceuticals to announce second quarter 2009 financial results on August 6, 2009 Jul 30 2009 Cyclacel completes previously announced registered direct offering Jul 24 2009 Cyclacel to raise up to $5.9 million in registered direct offering Jun 09 2009 Cyclacel to present at Annual Needham Biotechnology and Medical Technology Conference Jun 08 2009 Sapacitabine has anti-cancer activity in combination with targeted agents & other nucleoside analogs May 29 2009 Cyclacel Reports phase 2 sapacitabine data in patients with acute myeloid leukemia and myelodysplastic syndromes at 2009 Asco Annual Meeting May 29 2009 Cyclacel Reports initial phase 2 seliciclib data in patients with nasopharyngeal carcinoma at 2009 Asco Annual Meeting May 14 2009 Cyclacel Pharmaceuticals reports financial results for first quarter 2009 May 07 2009 Cyclacel Pharmaceuticals to announce release of First Quarter 2009 Financial Results and upcoming corporate events Apr 21 2009 Cyclacel & Dartmouth researchers report novel mechanism of action for seliciclib at AACR Apr 16 2009 Cyclacel Pharmaceuticals announces multiple presentations at American Association of Cancer Research Annual Meeting Pagination First page « first Previous page ‹ previous … Page 12 Page 13 Page 14 Page 15 Current page 16 Page 17 Page 18 Page 19 Page 20 … Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Dec 15 2009 Cyclacel receives NASDAQ notice of non-compliance Dec 15 2009 Cyclacel provides update on meeting with FDA to discuss pivotal study design for sapacitabine Dec 05 2009 Cyclacel reports Phase 2 sapacitabine data in acute myeloid leukemia and myelodysplastic syndromes at 2009 ASH annual meeting Dec 01 2009 Cyclacel to host conference call on Monday, December 7 to discuss new Phase 2 sapacitabine data to be presented at ASH Nov 30 2009 Sapacitabine phase 1 data published in acute leukemia and myelodysplastic syndromes Nov 17 2009 Cyclacel Pharmaceuticals to present Sapacitabine Phase 2 AML & MDS data at the upcoming American Society of Hematology meeting Nov 03 2009 Cyclacel Announces Third Quarter 2009 Financial Results Oct 30 2009 Cyclacel Receives Deficiency Notice From Nasdaq Global Select Market Oct 28 2009 Cyclacel reports survival data from phase 2 sapacitabine study in elderly patients with acute myeloid leukemia Oct 28 2009 Cyclacel Pharmaceuticals third quarter 2009 financial results conference call on Tuesday November 3 & upcoming conference presentations Oct 21 2009 Cyclacel Pharmaceuticals to present at BIO Investor Forum Sep 03 2009 Cyclacel to present at Annual Rodman & Renshaw Healthcare Conference Aug 28 2009 Cyclacel Pharmaceuticals announces receipt of NASDAQ notice Aug 06 2009 Cyclacel Pharmaceuticals announces second quarter 2009 financial results Jul 31 2009 Cyclacel Pharmaceuticals to announce second quarter 2009 financial results on August 6, 2009 Jul 30 2009 Cyclacel completes previously announced registered direct offering Jul 24 2009 Cyclacel to raise up to $5.9 million in registered direct offering Jun 09 2009 Cyclacel to present at Annual Needham Biotechnology and Medical Technology Conference Jun 08 2009 Sapacitabine has anti-cancer activity in combination with targeted agents & other nucleoside analogs May 29 2009 Cyclacel Reports phase 2 sapacitabine data in patients with acute myeloid leukemia and myelodysplastic syndromes at 2009 Asco Annual Meeting May 29 2009 Cyclacel Reports initial phase 2 seliciclib data in patients with nasopharyngeal carcinoma at 2009 Asco Annual Meeting May 14 2009 Cyclacel Pharmaceuticals reports financial results for first quarter 2009 May 07 2009 Cyclacel Pharmaceuticals to announce release of First Quarter 2009 Financial Results and upcoming corporate events Apr 21 2009 Cyclacel & Dartmouth researchers report novel mechanism of action for seliciclib at AACR Apr 16 2009 Cyclacel Pharmaceuticals announces multiple presentations at American Association of Cancer Research Annual Meeting Pagination First page « first Previous page ‹ previous … Page 12 Page 13 Page 14 Page 15 Current page 16 Page 17 Page 18 Page 19 Page 20 … Next page next › Last page last »
Dec 15 2009 Cyclacel provides update on meeting with FDA to discuss pivotal study design for sapacitabine
Dec 05 2009 Cyclacel reports Phase 2 sapacitabine data in acute myeloid leukemia and myelodysplastic syndromes at 2009 ASH annual meeting
Dec 01 2009 Cyclacel to host conference call on Monday, December 7 to discuss new Phase 2 sapacitabine data to be presented at ASH
Nov 17 2009 Cyclacel Pharmaceuticals to present Sapacitabine Phase 2 AML & MDS data at the upcoming American Society of Hematology meeting
Oct 28 2009 Cyclacel reports survival data from phase 2 sapacitabine study in elderly patients with acute myeloid leukemia
Oct 28 2009 Cyclacel Pharmaceuticals third quarter 2009 financial results conference call on Tuesday November 3 & upcoming conference presentations
Jul 31 2009 Cyclacel Pharmaceuticals to announce second quarter 2009 financial results on August 6, 2009
Jun 08 2009 Sapacitabine has anti-cancer activity in combination with targeted agents & other nucleoside analogs
May 29 2009 Cyclacel Reports phase 2 sapacitabine data in patients with acute myeloid leukemia and myelodysplastic syndromes at 2009 Asco Annual Meeting
May 29 2009 Cyclacel Reports initial phase 2 seliciclib data in patients with nasopharyngeal carcinoma at 2009 Asco Annual Meeting
May 07 2009 Cyclacel Pharmaceuticals to announce release of First Quarter 2009 Financial Results and upcoming corporate events
Apr 16 2009 Cyclacel Pharmaceuticals announces multiple presentations at American Association of Cancer Research Annual Meeting
